Calls for papers
-
Inhaler monitoring company Adherium has announced that its Smartinhaler platform has been rebranded as “Hailie.” The rebranding includes includes the Hailie asthma and COPD tracking app and Hailie sensors, which will soon launch in the… Read more . . .
-
Liquidia Technologies has named Jeri Thomas as its new Senior VP Commercial, responsible initially for commercial plans for the company’s LIQ861 treprostinil DPI, which is currently in Phase 3 development for the treatment of pulmonary… Read more . . .
-
The FDA has accepted Insned’s NDA for ALIS (amikacin liposome inhalation suspension) for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium complex (MAC), with a PDUFA date of September 28, 2018,… Read more . . .
-
The FDA informed Perrigo during a May 10, 2018 teleconference that the agency will issue a complete response letter to the company’s ANDA for its generic version of Teva’s ProAir albuterol MDI, Perrigo said. As… Read more . . .
-
MannKind Corporation announced that it has signed a deal with Cipla for marketing and distribution of Afrezza inhaled insulin in India. Cipla will be responsible for getting regulatory approval in India and will pay MannKind… Read more . . .
-
The Medical Devices Group at the University of Cape Town has designed a device to significantly reduce the force required to actuate an inhaler, the university has announced. The device, called “Easy Squeezy,” fits over… Read more . . .
-
TFF Pharmaceuticals, which recently announced that it had raised $14 million for the development of DPI formulations, has named former Arno Therapeutics CEO Glenn Mattes as its new Chief Executive Officer. Mattes’s career includes management… Read more . . .
-
US biopharmaceutical company NanoBio Corporation has changed its name to BlueWillow Biologics, which the company says “reflects its evolution to a vaccines-focused company, and commitment to advancing its novel intranasal technology to develop new vaccines… Read more . . .
-
Janssen Pharmaceutical has announced that data from a Phase 3 study demonstrated significantly significant and clinically meaningful reduction of symptoms in adult patients with treatment-resistant depression who received esketamine nasal spray plus an oral antidepressant… Read more . . .
-
Engage Therapeutics has announced the initiation of the double-blind, randomized Phase 2b StATES (Staccato Alprazolam Terminates Epileptic Seizures) trial of inhaled alprazolam in epilepsy patients who have seizures with a predictable pattern. The company said… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland